Early and Divergent Lipid Mediator Remodelling in Fast Versus Slow Skeletal Muscles of Female hSOD1<sup>G93A</sup> Mice.

Overview

1. Exercise and Muscle Physiology Research Group, Department of Movement Sciences, University of Leuven, Leuven, Belgium
2. MOVANT Research Group, Department of Rehabilitation Sciences and Physiotherapy, University of Antwerp, Wilrijk, Belgium
3. Leuven Brain Institute, Department of Neurosciences, University of Leuven, Leuven, Belgium
4. Laboratory of Neurobiology, VIB Center for Neuroscience, Leuven, Belgium
5. Department of Neurology, University Hospitals Leuven, Leuven, Belgium

Abstract

Background: Skeletal muscle atrophy in amyotrophic lateral sclerosis (ALS) drives loss of muscle strength, function and quality of life in ALS patients. The endocannabinoid system (ECS) regulates muscle homeostasis via regenerative and metabolic processes, and although ECS alterations have been reported in ALS neural tissues, ECS remodelling within ALS skeletal muscle has never been studied. This study investigated temporal and muscle type–specific ECS changes in ALS.

Methods: Female hSOD1G93A transgenic mice and nontransgenic littermates were studied at presymptomatic and symptomatic ages (56–138 days of age; n = 7–8/group). Endocannabinoids, N‐acyl‐ethanolamine congeners and inflammatory lipid mediators were quantified using targeted LC–MS/MS in the tibialis anterior (TA) and soleus (SOL) muscles. ECS‐related enzymes and receptors were assessed by immunoblotting and integrated with transcriptomic analyses of skeletal muscle biopsies from ALS patients (n = 5/group; ~63 years). To evaluate therapeutic relevance, ALS mice were treated with the fatty acid amide hydrolase (FAAH) inhibitor URB937 or vehicle (n = 10–11/group), and survival, body weight, welfare and motor function were assessed longitudinally.

Results: ALS caused severe atrophy in the predominantly fast‐twitch TA muscle (−76.5%; p < 0.01), while the slow‐twitch soleus was largely preserved (−14.4%; p < 0.01). Accordingly, the lipid perturbation due to ALS was more pronounced in the TA, reflected by extensive alterations in unsaturated fatty acids, hydroxy‐ and epoxy‐fatty acids (TA: 63% and SOL: 22% of lipid mediators different between ALS vs. NTG) and marked ECS remodelling, including elevated anandamide (+37.3%; p = 0.03) and multiple N‐acyl‐ethanolamine congeners (+76–102%; p < 0.05), reduced 2‐arachidonoylglycerol (−28%; p = 0.06), increased CB1 receptor expression (+93%; p < 0.01) and dynamic, age‐dependent regulation of FAAH (presymptomatic: −68%; p = 0.04, symptomatic: +21%; p = 0.02). In contrast, the SOL showed modest or opposite changes, consistent with its relative resistance to atrophy. Notably, ECS remodelling in the TA was already evident at presymptomatic age (e.g., CB1: +76%; p = 0.01) and the same ECS enzymes were affected in human ALS skeletal muscle transcriptomes (e.g., twofold decrease in FAAH; p FDR = 0.010). Despite evidence for a therapeutic potential, chronic peripheral FAAH inhibition with URB937 did not improve weight loss, motor functions and survival of ALS mice (all p > 0.05).

Conclusions: Muscle type–specific endocannabinoid system remodelling in ALS precedes overt neurological decline and might relate to degenerative features such as metabolic disturbance and inflammation. Although peripheral FAAH inhibition alone was insufficient to modify disease outcomes, these findings identify the endocannabinoid system as an integral component of ALS muscle pathology and support skeletal muscle lipid signalling as a potentially relevant early target for adjunctive therapeutic strategies.

Reproduced under the paper's license (CC BY), from the paper cited above.

Code

The paper links to its data, not to its authors' code: see the Data section.

Tracing map

A tracing map links a paper to the code its authors published: this paper has none, so it has no map.

Data

Datasets cited

• geo:GSE215424, at NCBI GEO; found in the text, “Human Transcriptomic Analyses”

Data Availability Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Reproduced under the paper's license (CC BY), from the paper cited above.

Versions

The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.

Version 1, 27 September 2026: the first record

Recorded: type, language, journal, volume, issue, pages, dates, 8 authors, 6 keywords, 12 MeSH terms, 2 funders, 62 references.

Cite

This paper

Dalle, S., Vanderbeke, K., Burg, T., Schouten, M., Lauriks, W., Hersmus, N., Van Den Bosch, L., & Koppo, K. (2026). Early and Divergent Lipid Mediator Remodelling in Fast Versus Slow Skeletal Muscles of Female hSOD1&lt;sup&gt;G93A&lt;/sup&gt; Mice. Journal of cachexia, sarcopenia and muscle, 17(4), e70357. https://doi.org/10.1002/jcsm.70357

Similar papers

The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.

[1] doi:10.1038/s41592-026-03057-2 [code]

CREsted: modeling genomic and synthetic cell-type-specific enhancers across tissues and species.

Journal: Nature methods

In common: mouse, author Ludo Van Den Bosch

[2] doi:10.1016/j.isci.2026.115565

Neuromuscular junction innervation and motor function are preserved by restoring muscarinic signaling in perisynaptic glia in ALS.

Journal: iScience

In common: other condition, mouse, cellular / molecular, 2 references

[3] doi:10.1186/s40478-026-02341-8 [code]

Intrathecal (G&lt;sub&gt;4&lt;/sub&gt;C&lt;sub&gt;2&lt;/sub&gt;)&lt;sub&gt;149&lt;/sub&gt; delivery in C9orf72-deficient mice yields mild motor dysfunction and ALS/FTD pathological hallmarks.

Journal: Acta neuropathologica communications

In common: other condition, mouse, cellular / molecular, 1 reference

[4] doi:10.1172/jci.insight.198842

Fatty acid amide hydrolase inhibition for treatment of amyotrophic lateral sclerosis.

Journal: JCI insight

In common: other condition, mouse, 1 reference

[5] doi:10.1016/j.xcrm.2026.102787 [code]

A human iPSC-derived sensory neuron platform for high-throughput discovery of neuroprotectants against chemotherapy-induced peripheral neuropathy.

Journal: Cell reports. Medicine

In common: other condition, mouse, 1 reference

[6] doi:10.1186/s40478-026-02391-y

Neuro-glial lipid imbalance in a Drosophila model of amyotrophic lateral sclerosis 8.

Journal: Acta neuropathologica communications

In common: other condition, cellular / molecular, 1 reference

[7] doi:10.1038/s41467-026-76522-3 [code]

Transcriptomic analysis of spinal V1 interneurons informs their multifunctional role in motor output.

Journal: Nature communications

In common: mouse, cellular / molecular, 1 reference

[8] doi:10.1080/21645515.2026.2664985

Immunotherapeutic landscape of amyotrophic lateral sclerosis: A bibliometric analysis of research trends, translational priorities, and collaboration networks (2006-2025).

Journal: Human vaccines & immunotherapeutics

In common: other condition, 1 reference

Contribute

The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.

Request its removal

To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).

Discussion: questions and error reports about this paper and its code, from signed-in readers and its authors. It opens with sign-in.

Reproductions: reports from readers who ran the authors' code: what they reproduced, with which environment, commit and data. It opens with sign-in.

Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.